Kornimate/medical-research-clean huggingface dataset:
compassion meditation for older adults

Conditions: Anxiety and Mood Disorders

Summary: some older veterans with psychological distress may under-utilize mental health services due to perceived stigma of symptom-focused interventions. this study was designed to examine the feasibility of a strengths-based compassion training intervention with veterans ages \> 55 years with anxiety or depressive symptoms. although this study was focused on feasibility if successful, this line of research could open the door to a novel and effective treatment that widens acceptance by older veterans with psychological distress.

many older veterans in va primary care clinics experience anxiety and depressive symptoms, but only a minority of these veterans seek care through va mental health services. research suggests that some older veterans with psychological distress under-utilize mental health services due to perceived stigma of treatments focused on mental health symptoms. however, prior research with civilians, including one study of veterans with ptsd, suggests a strengths-focused intervention that provides group training in compassion meditation may be effective in reducing negative emotions and increasing positive emotions and well-being. this project was designed to examine the feasibility of this approach with veterans ages \> 55 years with anxiety or depression. the study was designed to guide and support development of a future larger-size, more definitive follow-up project. . if successful, this line of research could open the door to a novel and effective treatment that widens acceptance by older veterans with psychological distress.

Eligibility criteria:
inclusion criteria: * va san diego healthcare system (vasdhs) patient * current mild-to-moderate anxiety or depressive symptoms as defined by scores between 5 and 14 on the patient health questionnaire (phq-9) and or generalized anxiety disorders scale (gad-7). * stated intention to attend the 10 group sessions at the scheduled times at the vasdhs in addition to the baseline and follow-up study assessment visits, as well as to complete the outside homework assignments * provides written informed consent for participation exclusion criteria: * no active suicidality/homicidality in the preceding six months * untreated alcohol or substance use disorders * changes to psychiatric medications within six months prior to the baseline evaluation * medical and/or psychiatric instability interfering with current ability to engage in the group sessions and outside homework assignments

Keywords: feasibility studies meditation, psychology
post-licensure safety study of isentress™ (raltegravir) in a united states managed care network (mk-0518-268)

Conditions: HIV-1 Infections

Summary: the objective of this study is to monitor health outcomes of interest (hoi) in participants with human immunodeficiency virus-1 (hiv-1) infection following treatment with raltegravir.

study participants contributed data to one or more of 3 cohorts: 1) historical cohort: hiv-infected participants treated with antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of kaiser permanente (kp) between 1 january 2000 and 12 october 2007 (date of market authorization for raltegravir in usa), 2) concurrent cohort: hiv-infected participant treated with a new non-raltegravir antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of kp on or after 12 october 2007, and 3) raltegravir cohort: hiv-infected participant treated with raltegravir in the course of ordinary clinical practice at the clinics and medical centers of kp on or after 12 october 2007. participants could contribute data to more than one cohort, but no overlap in follow-up time was allowed.

Eligibility criteria:
inclusion criteria: * historical cohort: hiv-infected participant treated with antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of kaiser permanente (kp) between 1 january 2000 and 12 october 2007 (date of market authorization for raltegravir in usa) * raltegravir cohort: hiv-infected participant treated with raltegravir in the course of ordinary clinical practice at the clinics and medical centers of kp on or after 12 october 2007 * concurrent cohort: hiv-infected participant treated with a new non-raltegravir antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of kp on or after 12 october 2007 * all participants must have at least one year of continuous membership with kp prior to date when the participant received the first dispensed prescription for study drug (index date) to allow for the assessment of medical and treatment history exclusion criteria: * less than 18 years of age * do not receive their medications through the kp pharmacy system * do not receive their laboratory examinations through the kp system * participating in the raltegravir phase iii or expanded access program

Keywords: hiv
long-term evolution of patients suffering from lumbar canal stenosis and supported by minimally invasive surgery: suivisteno

Conditions: Lumbar Spinal Stenosis

Summary: describe the functional evolution of patients at more than 10 years post intervention. describe the evolution of pain, satisfaction, quality of life of patients to more than 5 years pot intervention.

stenosis of the lumbar canal is a degenerative disorder, occurring most often in the elderly or middle aged, after 50 years. it most often results from the combination of 2 pathologies: the congenital narrowness of the lumbar canal is decompensated over time by the anatomical reorganizations generated by osteoarthritis. it is classically manifested by pain in the lower limbs, occurring almost exclusively in walking or in case of prolonged standing. this postural and dynamic character of the symptomatology is very characteristic of this pathology. the levels most often involved are l4 / l5 and l3 / l4. but, in case of extensive stenosis, other levels may be involved (l2 / l3, l5s1 or even l1 / l2). surgical treatment is obviously indicated from the outset in emergency situations or in cases of severe functional disability. it is most often proposed in case of failure of a complete and well-conducted medical treatment. in practice, in cases of tight canal stenosis, only a surgical operation can relieve the patient of pain and recover a normal walk. a minimal invasive technique: lumbar recalibration, which consists of decompression of the roots of the horse's tail under a microscope without fusion, without arthrodesis, provides a short-term functional benefit, even when grade 1 spondylisthesis exists. the interest of this technique for the patient is twofold: first aesthetic because the incision is much smaller than in the classical technique and becomes almost invisible after a few months; then and above all it is functional because, by preserving the paravertebral muscles that it allows, this procedure is less painful and allows a lift the same day and an earlier recovery activities. very few scientific publications compare different surgical techniques, and even fewer results are available on the long-term future of patients.

Eligibility criteria:
inclusion criteria: * patients operated within the institution between 2006 and 2008 * major patient (18 years old or over). * francophone. * affiliated to a social security scheme exclusion criteria: * pregnant or lactating women according to article l1121-5 of the csp. * vulnerable persons according to article l1121-6 of the csp. * major persons placed under guardianship or curatorship
home-based dual-task training for older adults

Conditions: Mild Cognitive Impairment

Summary: this project is focused on conducting a home-based, thinking while moving exercise intervention for adults 65 years or older, who have mild cognitive impairment, that will integrate several effective training modalities including non-contact cardio-kickboxing, stepping exercise, balance/functional training, and muscle strengthening. cognitive function, physical function, and dual-task abilities will be assessed over the 12-week intervention and comparisons will be made between participants in the exercise intervention and control participants receiving no intervention.


Eligibility criteria:
inclusion criteria: * 65 years or older * male or female * screened positive for mild cognitive impairment (montreal cognitive assessment score 23 to 26 points * having no absolute contraindications to non-physician supervised exercise. exclusion criteria: * lower-body amputation * non-english language speaker
detection of plasma dna methylation in peripheral blood from patients with resectable liver cancer

Conditions: Resectable Hepatocellular Carcinoma

Summary: this study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). the development of novel cancer biomarkers for liver cancer may help in clinical decision making and lead to improvements in patient outcomes by facilitating prediction of the response to specific treatments, improved monitoring of patients on treatment, and better prognostication of patient outcomes, thus improving stratification for clinical trials.

primary objectives: i. to isolate plasma deoxyribonucleic acid (dna) methylation panel from the peripheral blood of treated patients with hepatocellular carcinoma that will correlate with disease progression or measurable residual disease. ii. to correlate the mutations/ dna methylation in peripheral blood with those identified in parallel tumor samples from the same patients with hepatocellular (hcc). outline: patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. patients' previously collected tissue samples are analyzed. patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years.

Eligibility criteria:
inclusion criteria: * patient has planned resection or ablation of suspected hepatocellular carcinoma * patient is classified as resectable t1/t2 hepatocellular carcinoma (hcc) (solitary tumors less than or equal to 2 cm or solitary tumors without vascular invasion \> 2cm or solitary tumor with vascular invasion \> 2cm, or multiple tumors, none \> 5cm) or bclc stage a (single lesion of any size or 3 nodules or less with each being 3cm or less) exclusion criteria: * patient is younger than 18 years of age * females who are pregnant or attempt to become pregnant * patient with significant anemia (hemoglobin \[hb\] \< 7g/dl) * patient has known cancer outside of the liver 5 years prior to current blood collection (not including basal cell or squamous cell skin cancers) * patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection * patient has had an intervention to completely remove current target pathology * target pathology is a recurrence of previously treated hcc * patient has had prior resection or ablation for target lesion * patient has had prior or active chemotherapy or radiation for target lesion
effect of protein-restricted diet on nitrogen balance and residual renal function in peritoneal dialysis (pd) patients

Conditions: Chronic Kidney Disease; Peritoneal Dialysis

Summary: current therapy recommendations suggest a low protein diet to preserve residual renal function (rrf) before the start of dialysis, but a higher protein intake during dialysis to prevent protein-energy wasting (pew). we conducted a randomized trial to test whether low protein intake also during treatment with peritoneal dialysis (pd) would be safe and associated with a preserved rrf.

dietary protein is the major source of nitrogen excreted as urea by the kidney, and a decreased protein intake has been associated with a retardation of kidney function loss in non-dialysis chronic kidney disease (ckd) patients. while a low protein diet is recommended to end-stage renal disease (esrd) patients before the start of dialysis to preserve residual renal function(rrf), current therapy recommendations in dialysis are for a normal protein intake of no less than 1.2 g of protein/kg ideal body weight (ibw)/day to prevent protein-energy wasting (pew). we hypothesized that a lower protein intake would be safe and able to slow the loss of rrf also in dialysis patients and conducted two prospective, randomized trials involving a total of 94 peritoneal dialysis (pd) patients to test our hypothesis.

Eligibility criteria:
inclusion criteria: * age 18-80 years * stable peritoneal dialysis since at least 1 month * with renal function exclusion criteria: * a high probability (assessed by the recruiting physician) of receiving a kidney transplant within one year * overt infection within the last month * poor compliance in previous dietary prescriptions or irregular check-ups * persistent anorexia, vomiting or diarrhea within the last month * a crp of more than 30 mg/dl * presence of wasting diseases such as cancer or tuberculosis

Keywords: nitrogen balance malnutrition chronic kidney disease diet glomerular filtration rate
artimes pro low profile dilatation catheters for pre-dilatation in patients with symptomatic ischemic heart disease

Conditions: Coronary Artery Disease; Heart Disease, Ischemic; Coronary Stenosis

Summary: this is a prospective, non-randomized, open label, multi-center study including 60 patients with symptomatic ischemic heart disease with 70%-100% coronary artery stenoses and occlusions enrolled and treated in this investigational device study.

patients who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional ptca catheters and stents, according to standard of care will be enrolled in this study. a maximum of 60 subjects with native coronary artery lesions or occlusions will be treated using the artimes pro balloon dilatation catheters in a 3:1 ratio using the 1.0mm and 1.25mm dilatation catheters for pre-dilatation and will complete the study within the u.s. this equals 45 patients treated using the 1.0mm dilatation catheter, and 15 patients treated with the 1.25mm dilatation catheter for a total of 60 subjects enrolled and treated.

Eligibility criteria:
inclusion criteria: * at least 18 years of age; * willing and able to provide informed consent; * willing and able to meet all study requirements; * patients with symptomatic ischemic heart disease due to stenotic lesions or occlusions in coronary arteries that are amenable to percutaneous coronary interventions; * patients who tolerate dapt exclusion criteria: * a known hypersensitivity or contraindication to aspirin, heparin, or bivalirudin, anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-medicated; * lvef \< 30%; * evidence of an acute myocardial infarction within 72 hours of the intended index procedure; * planned treatment of unprotected left main disease; * history of cerebral vascular accident (cva) within 6 months prior to consideration for this study; * transient ischemic attack (tia) within 6 months prior to consideration for this study; * active peptic ulcer or upper gastrointestinal (gi) bleeding within 6 months prior to consideration for this study; * history of bleeding diathesis or coagulopathy; * refuses blood transfusions; * any general contraindication to revascularization procedures; * pregnant or lactating; * in the judgement of the investigator, patient is not a suitable candidate for this study.
prediction model fo screening and diagnosis of prostate cancer in psa gray zone based on serum phi combined with tpv

Conditions: Prostate Cancer; PSA

Summary: prostate cancer (pca) is a high incidence tumor of elderly men. in recent years, its incidence has rapidly increased in china. serological examination of prostate-specific antigen (psa) is particularly important in the early diagnosis of pca, but its specificity is lower in gray areas with psa between 4-10 ng / ml. proposition of prostate health index (phi) strengthens the specificity of psa gray area prostate cancer diagnosis, but the composition of the index only relies on serological examination, neglects imaging indicators, and cannot be comprehensively evaluated. based on the preliminary basis of phi research in the undergraduate department, combined with ultrasound imaging indicators of total prostate volume (tpv), this research group prospectively analyzed the efficacy of phi combined with tpv to predict prostate cancer in patients with psa gray areas, and established an improved version of phi-tpv combination. the prediction model mphi assesses the sensitivity of the new model to predict the risk of prostate cancer in the chinese population, provides data support for puncture decisions of middle-aged and elderly male patients in the gray area of psa in china, and provides reference and guidance for the individualized prevention and treatment of prostate cancer.


Eligibility criteria:
inclusion criteria: 1. patient\> 45 years of age 2. abnormal serum psa 3. prostate nodules found by dre 4. abnormal mri or trus finding exclusion criteria: 1. incomplete medical history 2. poor quality of serum samples 3. bacterial acute prostatitis diagnosed within 3 months before biopsy 4.5α reductase inhibitors, anabolic steroids, or antiandrogen drugs taken within 12 months before biopsy 5.previous prostate biopsy history.

Keywords: prostate cancer psa phi ultrasound tpv
anti-adhesive effect and safety of a mixed solid of poloxamer, gelatin and chitosan(mediclore®) after axillary dissection for breast cancer

Conditions: Breastcancer; Surgery: Axillary Dissection

Summary: anti-adhesive effect and safety of a mixed solid of poloxamer, gelatin and chitosan(mediclore®) after axillary dissection for breast cancer

a multicenter double-blinded, randomized study

Eligibility criteria:
inclusion criteria: * the patients needed axillary dissection in breast cancer * written informed consent * patients without clinically significant lab * the patients who are diagnosed 'positive for metastasis' by sentinel lymph node biopsy exclusion criteria: * having enrolled another clinical trials within 1 month * immunosuppression or autoimmune disease * anticoagulant, general steroids within a week from surgery * incompatible medications * serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies)
risk factors of necrotizing enterocolitis in premature newborns

Conditions: Necrotizing Enterocolitis of Newborn; Risk Factors

Summary: with premature newborn increase survival, the risk of serious neonatal morbidity, such as necrotizing enterocolitis (nec), also increased. nec affects between 2 to 7% of premature infants including 5 to 22% of newborns weighing less than 1000 g. nec is an acquired disease, caused by inflammation of the intestinal lining. it is the most common life-threatening gastrointestinal emergency of prematurity, associated with a significant morbidity and mortality. the etiology and physiopathology are multifactorial, complex, and remain poorly understood. the mechanism of the lesions seems to involve factors including immaturity of the intestinal barrier and the immune system, microvascular imbalance, disturbed gut flora and systemic inflammation. despite improved knowledge about this disease, the proportion of surviving patients has not improved for several years. it frequently leads to long-term sequelae depending on the severity of the nec and its treatment. early diagnosis and early treatment of nec may reduce the risk of mortality and morbidity. the aim of this retrospective bi-centric study is to look for risk factors allowing the prediction of nec in order to prevent and improve the early management of this disease.


Eligibility criteria:
inclusion criteria: * premature newborns (\< 37 weeks of gestation) having done a necrotizing enterocolitis stage ii or iii according to bell's criteria. exclusion criteria: * children term born (\> 37 weeks of gestation) * necrotizing enterocolitis during an hospitalisation outside the nicu of nancy or lyon * malformation or pre-existing digestive pathology * complex or severe malformative pathologies
intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants

Conditions: Ischemic Stroke

Summary: do-it is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (ivt) is safe and improves functional outcome in ischemic stroke patients with recent direct oral anticoagulant (doac) intake. for this purpose, information on 2800 adult participants experiencing an acute ischemic stroke will be obtained at several high-volume international stroke centers and divided into three groups: ivt with recent doacs intake (doac+ivt), and recent doac intake not receiving ivt (doac) as well as anonymized patients without doac receiving ivt. the patients are followed up for 90 days after the index event. treatment recommendations from the described observations. the investigators hypothesize that also more liberal decisions for ivt in patients with recent doac intake are not associated with an increased risk for symptomatic intracerebral hemorrhage (sich) and result in better functional outcome at 3 month.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of acute ischemic stroke with indication for ivt according to applicable guidelines 2. time from symptom onset or last known well \<12 hours 3. admission nihss of 2 points or more 4. either doac ingestion within 48 hours prior to expected timepoint of ivt bolus, or patient with an ongoing prescription of doac, but exact timepoint of last intake not verifiable in the emergency setting. (regardless of whether intravenous thrombolysis was given) or doac prescription (any intake within the last 7 days) and receiving intravenous thrombolysis 5. informed consent (if obtainable and in those international sites where this is legally required) for the prospective part exclusion criteria: 1. patient refused the use of biological data for research purposes (switzerland) 2. any acute or subacute intracranial hemorrhage (ich) identified by admission ct or mri on brain scan 3. documentation of any other absolute contraindications to ivt in the medical record 4. significant pre-stroke disability (mrs score of 5), including known advanced dementia 5. known (serious) sensitivity to alteplase/tenecteplase or any of the excipients 6. pregnancy or lactating women.

Keywords: doac (direct oral anticoagulants) noac (novel oral anticoagulants) anticoagulation r-tpa (tissue-type plasminogen activator) alteplase tenecteplase rivaroxaban apixaban dabigatran edoxaban